Emerging therapies for portal hypertension in cirrhosis

Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C–Related Compensated Cirrhosis

(2016) Arpan Mohanty et al.   GASTROENTEROLOGY

Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients

(2016) Lars Bossen et al.   HEPATOLOGY

Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study

(2015) Enric Reverter et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study

(2015) Wolfgang Kreisel et al.   DIGESTIVE AND LIVER DISEASE

Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial

(2015) Priscila Pollo-Flores et al.   DIGESTIVE AND LIVER DISEASE

Pathophysiology and a Rational Basis of Therapy

(2015) Jordi Gracia-Sancho et al.   DIGESTIVE DISEASES

Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension

(2015) Rajeshwar P. Mookerjee et al.   JOURNAL OF HEPATOLOGY

Expanding consensus in portal hypertension

(2015) Roberto de Franchis   JOURNAL OF HEPATOLOGY

Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis

(2015) Dmitry Victorovich Garbuzenko   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis

(2014) E. Sinagra et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacologic Management of Portal Hypertension

(2014) Annalisa Berzigotti et al.   Clinics in Liver Disease

Beta-blockers in cirrhosis: Therapeutic window or an aspirin for all?

(2014) Alberto Ferrarese et al.   JOURNAL OF HEPATOLOGY

Relationship between Tetrahydrobiopterin and Portal Hypertension in Patients with Chronic Liver Disease

(2014) Won Ki Hong et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis

(2014) Fernando J. Barreyro et al.   LIVER INTERNATIONAL

Activation of the Mas Receptor by Angiotensin-(1–7) in the Renin–Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis

(2013) Josephine A. Grace et al.   GASTROENTEROLOGY

Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats

(2013) Eugenio Rosado et al.   HEPATOLOGY

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

Hemodynamic effects of continuousversusbolus infusion of terlipressin for portal hypertension: A randomized comparison

(2013) Chao Ding et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Simvastatin maintains function and viability of steatotic rat livers procured for transplantation

(2013) Jordi Gracia-Sancho et al.   JOURNAL OF HEPATOLOGY

The burden of liver disease in Europe: A review of available epidemiological data

(2013) Martin Blachier et al.   JOURNAL OF HEPATOLOGY

The changing role of beta-blocker therapy in patients with cirrhosis

(2013) Phillip S. Ge et al.   JOURNAL OF HEPATOLOGY

Beta-blockers in portal hypertension: new developments and controversies

(2013) Dhiraj Tripathi et al.   LIVER INTERNATIONAL

Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial

(2012) Andrea De Gottardi et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats

(2012) M. D'Amico et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

(2012) Erica Villa et al.   GASTROENTEROLOGY

The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1

(2012) Aleksander Krag et al.   GUT

Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction

(2012) Vincenzo La Mura et al.   HEPATOLOGY

Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis

(2012) Jiannis Vlachogiannakos et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Functional aspects on the pathophysiology of portal hypertension in cirrhosis

(2012) Juan-Carlos García-Pagán et al.   JOURNAL OF HEPATOLOGY

PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats

(2012) Aina Rodríguez-Vilarrupla et al.   JOURNAL OF HEPATOLOGY

Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats

(2012) Maeva Guillaume et al.   JOURNAL OF HEPATOLOGY

Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats

(2012) Marco Di Pascoli et al.   JOURNAL OF HEPATOLOGY

The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial–stellate cell deactivation induced by statins

(2012) Giusi Marrone et al.   JOURNAL OF HEPATOLOGY

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

(2012) Marco Metra et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Hepatorenal syndrome

(2012) Jan Lata   WORLD JOURNAL OF GASTROENTEROLOGY

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study

(2011) M. Pinter et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis

(2011) Didier Lebrec et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

(2011) Romain Coriat et al.   PLoS One

Current status of novel antifibrotic therapies in patients with chronic liver disease

(2011) Michal Cohen-Naftaly et al.   Therapeutic Advances in Gastroenterology

Sildenafil Has No Effect on Portal Pressure but Lowers Arterial Pressure in Patients With Compensated Cirrhosis

(2010) Puneeta Tandon et al.   Clinical Gastroenterology and Hepatology

Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability

(2010) Kuei-Chuan Lee et al.   CLINICAL SCIENCE

Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension

(2010) Jaume Bosch et al.   JOURNAL OF HEPATOLOGY

Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis

(2010) Puneeta Tandon et al.   JOURNAL OF HEPATOLOGY

Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats

(2010) Héctor García-Calderó et al.   JOURNAL OF HEPATOLOGY

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Varices and Variceal Hemorrhage in Cirrhosis

(2010) Guadalupe Garcia-Tsao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis

(2009) J. VLACHOGIANNAKOS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease

(2009) Hong-Qiang Feng et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial

(2009) Juan G. Abraldes et al.   GASTROENTEROLOGY

Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites

(2009) A Krag et al.   GUT

Angiogenesis in liver disease

(2009) Mercedes Fernández et al.   JOURNAL OF HEPATOLOGY

The clinical use of HVPG measurements in chronic liver disease

(2009) Jaime Bosch et al.   Nature Reviews Gastroenterology & Hepatology

Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis

(2009) Jian Liang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease

(2008) Don C. Rockey   Clinics in Liver Disease

Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension

(2008) B Lavina et al.   GUT

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

(2008) Marc Mejias et al.   HEPATOLOGY

The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats

(2008) Marc Mejias et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats

(2008) Vasilica Matei et al.   JOURNAL OF HEPATOLOGY

The management of portal hypertension: Rational basis, available treatments and future options

(2008) Jaime Bosch et al.   JOURNAL OF HEPATOLOGY

Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis

(2008) Jens Otto Clemmesen et al.   WORLD JOURNAL OF GASTROENTEROLOGY